Enzymatica AB (publ) (STO: ENZY)

Market Cap	339.83M
Revenue (ttm)	44.95M
Net Income (ttm)	-55.95M
Shares Out	173.38M
EPS (ttm)	-0.33
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	76,411
Open	1.950
Previous Close	1.920
Day's Range	1.890 - 2.040
52-Week Range	1.650 - 4.250
Beta	-0.04
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 7, 2024

About Enzymatica AB

Enzymatica AB (publ), a life science company, develops and sells products that treat and alleviate infections and symptoms in the upper respiratory tract. The company’s product includes ColdZyme, a mouth spray to treat and alleviate cold and flu symptoms. It also provides enzyme formulations for skin care. The company offers its products through contract organizations and partner agreements with distributors who sell the products under the ViruProtect, STADAProtect, and Bisolviral brand names. Enzymatica AB (publ) was incorporated in 2007 and i...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2007
• Employees: 18
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: ENZY

Financial Performance

In 2023, Saniona AB's revenue was 16.84 million, an increase of 10.19% compared to the previous year's 15.28 million. Losses were -95.81 million, -54.71% less than in 2022.